It differentiates between fat mass and muscle mass changes, helping ensure healthy fat loss
If an individual meets their deductible, it is satisfied for that member, and claims begin paying with coinsurance/copays
These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
As we age, mitochondrial function declines, leading to increased oxidative stress, reduced ATP production, energy deficiency, and the accumulation of cellular damage over time